Coronavirus Update: GSK Signs Non-Coronavirus Deal With CureVac On mRNA Vaccines

Plus: Pfizer And BioNTech Strike UK Deal

Deal brings in new funding and commercial partner for CureVac, and gives GSK greater stake in fast-developing mRNA field.    

CureVac_HQ
CureVac HQ • Source: Shutterstock

GlaxoSmithKline plc has signed a deal with CureVac to develop and commercialize up to five mRNA-based vaccines and monoclonal antibodies targeting infectious diseases, paying £104m ($130m) upfront and acquiring a stake in the company worth £130m ($163m).

CureVac also stands to receive development and regulatory milestone payments of up to £277m (€320m), commercial milestone payments of up...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from COVID-19

More from Scrip